🔗 Share this article

As America undertakes sweeping revisions to its vaccine recommendations, a particular individual appears unexpectedly: Høeg, an American of Danish descent sports medicine doctor and public health researcher who initially gained attention by casting doubt on coronavirus vaccinations during the global health crisis and has zeroed in on possible fatalities following Covid vaccination in her short tenure at the FDA.

Proposed Overhauls to Pediatric Immunization Program

Agency leaders had intended to reveal radical revisions to the childhood vaccine schedule recently, aligning the US with Denmark’s vaccine program, sources say – a substantial departure that would place the US out of alignment with many the international standard with little proof for public health gain. The planned update has been pushed back until the new year.

Instead of the top vaccines chief, Tracy Beth Høeg is scheduled to address the audience at the gathering. She was newly appointed acting director of the FDA’s CDER, the fifth individual to lead the office this calendar year.

A New Direction at the Agency

This interim role might represent a closer partnership between the pharmaceutical and vaccine divisions as Høeg and Prasad consolidate power at the agency – and it suggests a increased emphasis upon reevaluating already-approved immunizations at the FDA.

The new acting director has often pushed for ending specific pediatric shot schedules in the US to become more like Denmark, a country with comprehensive healthcare and a citizenry about the population of the state of Wisconsin.

So far comments, she has persisted in emphasizing on vaccination policy – traditionally the responsibility of Dr. Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of medication approval.

Doubts Over Qualifications

Høeg has little discernible experience in pharmaceutical research, oversight or leadership, which has been standard for past heads of the Center for Biologics Evaluation and Research. She has served at the FDA as a senior adviser to the agency head and the vaccine center since earlier this year.

“She doesn’t seem to have the requisite experience” for leading the pharmaceutical oversight division, said Jonathan Howard. “She’s never run a randomized controlled trial. She lacks experience in leading a large organization. She has no expertise in industry regulation.”

Previous directors of the center would “be deeply familiar with regulatory frameworks and the underlying principles of pharmaceutical innovation”, noted Dr. Janet Woodcock. “Objectively, she has not acquired the kind of background that prior appointees who headed CBER have had.”

CDER has an immense range of responsibilities at the FDA, Woodcock pointed out.

“The public just focuses on the innovative therapies, but the generic drug division approves thousands of off-brand pharmaceuticals. There’s a biosimilars program, non-prescription drug unit and other areas, and each of these have to be looked after,” Dr. Woodcock noted. “The thing you don’t keep your eye on, that is the part that I always told people is going to cause problems.”

Additionally, a substantial leadership aspect to the job, which oversees in excess of 5,000 staff members. “It is a huge administrative position, if you perform it correctly,” Woodcock concluded.

Agency Reaction and Contentious Policies

Regarding concerns about Høeg’s credentials and whether this assignment represents greater collaboration among agency officials on vaccines, a press secretary said that the “questions are based on flawed premises”.

“Her resume matches the duties of her job,” the spokesperson explained, noting the months Dr. Høeg spent advising the agency head on “pharmaceutical safety and regulatory science, including computational safety modeling and immunization monitoring”.

As the temporary head, Høeg inherits the commissioner’s recently launched expedited review system, a contentious expedited therapy clearance system that reportedly troubled her predecessors. “How are these medications being picked for this voucher program? Who makes the choices?” Dr. Howard asked. “There’s a lot of secrecy occurring at the regulatory body right now.”

Overall, he remarked, “the agency seems to be moving towards laxer rules of pharmaceuticals, aside from shots.”

Public History on Vaccines

With vaccines, Dr. Høeg has a more established, if troubling, past, critics observe. She published a analysis using unverified crowd-sourced reports to determine the frequency of heart inflammation after Covid vaccination. She counseled the Florida surgeon general Dr. Joseph Ladapo, who allegedly have changed statistics to suggest COVID-19 vaccines are more dangerous than they are.

Part of her “policy goals” for the current administration included revising rules for novel immunizations and halting “optional” vaccines, she stated after the election on a podcast. At the FDA, Dr. Høeg has allegedly floated the idea of excluding adolescent males from getting Covid vaccines.

“She’s an complete dogmatist who begins with her preconceived notions and tailors the evidence to fit the data in a highly deceptive, dishonest fashion,” Howard said.

Gaining Influence and a “Push for Payback”

Dr. Høeg became part of fellow contrarians, {like|